期刊文献+

改良Bu-CTX2预处理外周血干细胞移植治疗血液肿瘤

全文增补中
导出
摘要 目的观察采用改良 Bu-CTX2预处理方案的异基因外周血造血于细胞移植(allo-PBSCT)治疗血液肿瘤的疗效。方法用改良 Bu-CTX2预处理方案的 allo-PBSCT 治疗白血病、淋巴瘤8例。预处理方案:阿糖胞苷,白消安,环磷酰胺,甲基环己亚硝脲,抗胸腺细胞球蛋白。结果 8例患者完全植入,+15 d~+25d 白细胞(WBC)】1.0×10~9/L,+12d~+51d血小板(Ph)】20×10~9/L。例1、例7及例8出现急性移植物抗宿主病(aGVHD)Ⅰ度;例4出现肝静脉闭塞综合征(VOD)、aGVHD Ⅰ度、出血性膀胱炎(HC);例5aGVHDⅣ度。例2移植后6个月复发,放弃治疗死亡;其余正常生活或工作。结论采用改良 Bu-CTX2 预处理方案的 allo-PBSCT 治疗血液肿瘤是安全有效的方法。
出处 《白血病.淋巴瘤》 CAS 2007年第6期462-463,共2页 Journal of Leukemia & Lymphoma
基金 海南省自然科学基金立项资助项目(2004指导性项目)
  • 相关文献

参考文献9

  • 1黄晓军.HLA不合的血缘关系供者异基因造血干细胞移植[J].中华血液学杂志,2006,27(8):575-576. 被引量:7
  • 2贾永前,刘霆,徐才刚,牛挺,孟文彤,鲁建春,王晖,冷亚美.MCC与BuCy预处理方案在慢性髓性白血病异基因干细胞移植后长期疗效的比较[J].四川大学学报(医学版),2006,37(2):226-229. 被引量:5
  • 3Gluckman E,Rocha V,Chevret S.Results of unrelated umbilical cord blood hematopoietic stem cell transplantation. Reviews in Clinical and Experimental Hematology . 2001
  • 4Hassan M,Nilsson C,Hassan Z,et al.A phaseⅡtrial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation:500 mg/m(2) as a optimal total dose for conditioning. Bone Marrow Transplantation . 2002
  • 5Kang H J,Shin H Y,Choi H S,et al.Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood a-cute myeloid leukemia. Bone Marrow Transplantation . 2004
  • 6Andersson,BS,Kashyap,A,Gian,V.Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biology of Blood and Marrow Transplantation . 2002
  • 7Grochow LB.Parenteral busulfan:is therapeutic monitoring still warranted?. Biology of Blood and Marrow Transplantation . 2002
  • 8Ringden O,Run T,Lenhoff S,et al.A randomized trial comparing busulfan VS total body irradiation in allogeneic marrow transplantation recipients with hematological malignancies. Transplantation Proceedings . 1994
  • 9McDonald,GB,Sharma,P,Matthews,DE,Shulman,HM,Thomas,ED.Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology . 1984

二级参考文献8

  • 1Barret J. Allogeneic stem cell transplantantion for chronic myeloid leukemia. Semin hematol,2003;40(1):59-71.
  • 2Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet,1998;352(9134):1087-1092.
  • 3Berman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol,1988;6(10):1562-1568.
  • 4Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood,1994;84(6):2036-2043.
  • 5Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analogcontainingpreparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood,2001;97(3):631-637.
  • 6Reuven Or, Michael YS, Igor R, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood,2003;101(2):441-445.
  • 7Morgan M,Dodds K,Atkinson K,et al. The toxicity of busulfan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol,1991;77(4):529-534.
  • 8贾永前,羊裔明,刘霆,吴谨绪,贺建清,朱焕玲,孟文彤,邓长安.MAC预处理方案在慢性粒细胞白血病异基因骨髓移植中的应用[J].中华血液学杂志,1998,19(8):431-432. 被引量:1

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部